Ovid Therapeutics Inc.

OVID ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $13.2M $26.3M $27.0M $44.9M $187.8M $72.0M $41.9M $36.5M
Accounts Receivable
Inventory
Total Current Assets $74.4M $55.9M $109.6M $131.4M $190.5M $74.8M $79.8M $44.3M
Property, Plant & Equipment $252.0K $433.0K $769.0K $1.1M $242.8K $135.6K $68.4K $69.9K
Goodwill
Intangible Assets (Excl. Goodwill) $0 $100.0K $200.0K $222.1K $164.1K $319.0K $467.0K $392.0K
Total Assets $150.9M $92.2M $144.0M $155.3M $194.5M $75.9M $80.8M $47.6M
Liabilities
Accounts Payable $2.0M $3.2M $3.7M $2.0M $7.1M $5.4M $3.3M $3.8M
Total Current Liabilities $8.3M $10.5M $11.5M $7.0M $14.8M $22.1M $10.5M $8.8M
Long-Term Debt
Total Liabilities $20.3M $23.9M $56.2M $23.0M $14.8M $32.3M $10.8M $8.8M
Stockholders' Equity
Retained Earnings $-321.7M $-304.3M $-277.9M $-225.5M $-171.4M $-294.2M $-213.2M $-152.7M
Total Stockholders' Equity $130.7M $68.2M $87.8M $132.3M $179.7M $43.6M $70.0M $38.8M
← Newer Page 1 of 2 Older →